Recent developments highlight leadership changes, regulatory approvals, commercial launches, and strategic partnerships.

• RemSleep announced the passing of founder Thomas Wood and appointed Jeffrey Marshall as CEO and director in March 2026 [N1].
• The company announced the full commercial launch of its DeltaWave(TM) CPAP mask and nasal pillow system in February 2026 [N2].
• RemSleep outlined its Q1 2026 commercial strategy including expanded FDA applications, B2B launch preparations, and institutional market entry in January 2026 [N3].
• The company published a detailed DeltaWave(TM) launch plan in October 2025 [N4].
• RemSleep entered a formal agreement with a major distributor in May 2025 to support product commercialization [N5].
• Prior to that, the company was in the process of signing a major distributor agreement in April 2025 [N6].
• RemSleep prepared to launch a new FDA cleared CPAP pillows mask to market in February 2025 [N7].
• The company provided a shareholder update in November 2024 outlining progress and plans [N8].

The company has achieved key regulatory milestones including FDA 510(k) clearance and Medicare PDAC coding approval, facilitating commercial launch. Recent leadership changes bring experienced management focused on scaling operations. Formal distributor agreements and outlined commercial strategies indicate progress toward market expansion. The proprietary DeltaWave(TM) product line and patent portfolio support potential competitive positioning in the sleep therapy device market.

RemSleep operates with limited disclosed financial resources and reported a significant net loss in the latest fiscal year. The current ratio below 1.0 indicates potential liquidity constraints. The company faces execution risks related to commercial scaling, regulatory compliance, and market acceptance. Leadership transition following the founder's passing may introduce operational uncertainties. The OTCQB listing and smaller reporting status reflect a relatively early-stage public company with limited visibility into customer base and revenue diversification.

RemSleep's moat is centered on its proprietary DeltaWave(TM) technology, which has received FDA clearance and Medicare coding approval, enabling market access. The company has also secured distribution agreements and holds patents related to its products. However, as a smaller reporting company with limited disclosed financial scale and market penetration, its competitive advantages are still developing and subject to execution risks.

• Liquidity and Financial Performance: The company reported a net loss of $3.02 million for fiscal year 2025 and has a current ratio below 1.0, indicating potential liquidity challenges.
• Leadership Transition: The passing of the founder and appointment of a new CEO in early 2026 may impact strategic continuity and operational execution.
• Regulatory and Commercial Execution: While FDA clearance and Medicare coding approvals have been obtained, successful market adoption and scaling depend on effective commercialization and distributor partnerships.

• RemSleep Holdings Inc. is a smaller reporting company incorporated in Georgia, USA, trading OTCQB under ticker RMSL.
• The company develops and commercializes medical devices related to sleep therapy, notably the DeltaWave(TM) CPAP mask and nasal pillow system.
• DeltaWave(TM) received FDA 510(k) clearance and expanded clearance for its nasal pillow system.
• The company has received Medicare PDAC coding approval for the complete DeltaWave product portfolio.
• RemSleep has entered formal agreements with major distributors to commercialize its products.
• The company announced the full commercial launch of DeltaWave(TM) in February 2026.
• Leadership changed in March 2026 with the passing of founder Thomas Wood and appointment of Jeffrey Marshall as CEO and director.
• Jeffrey Marshall's employment agreement includes base salary and performance-based equity incentives tied to milestones.
• Anita Michaels serves as Chairman of the Board and majority shareholder, providing clinical and financial oversight.
• Financial snapshot as of December 31, 2025, shows cash and equivalents of $214,514, current assets of $265,193, current liabilities of $299,641, resulting in a current ratio of 0.89 and cash ratio of 0.72.
• Revenue for fiscal year 2025 was $16,721 with a net loss of $3,020,300 and zero reported basic and diluted EPS.
• No material legal proceedings or claims are pending or threatened against the company or its officers.
• The company has engaged in ongoing FDA regulatory submissions and updates since 2021, including substantive review of 510(k) submissions for DeltaWave.
• RemSleep has outlined commercial strategies including expanded FDA applications, B2B launch preparations, and institutional market entry plans.
• The company has issued multiple shareholder updates and marketing plans since 2024.
• RemSleep Holdings is focused on scaling commercial operations under new executive leadership.